Seala (VG101) / Bionovo 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   18 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Seala (VG101) / Bionovo
ACTRN12622000933752: A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of VGL101 in Healthy Adults

Completed
1
30
 
Vigil Neuroscience, Inc, Vigil Neuroscience, Inc
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
 
 
NCT05911685: Evaluation of the Safety and Efficacy of a Novel SeaLA™ Left Atrial Appendage Occluder

Active, not recruiting
N/A
163
RoW
SeaLA™ left atrial appendage occluder
Hangzhou Dinova EP Technology Co., Ltd
Atrial Fibrillation
01/21
01/25
NCT05731882: First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder

Recruiting
N/A
10
RoW
E-SeaLA, CardioPulse PFA system
Hangzhou Dinova EP Technology Co., Ltd
Nonvalvular Atrial Fibrillation
06/24
08/24

Download Options